BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 11842758)

  • 1. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.
    Bolla M; de Reijke TM; Zurlo A; Collette L
    Front Radiat Ther Oncol; 2002; 36():81-6. PubMed ID: 11842758
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 3. Endocrine therapy of prostate cancer.
    Bare RL; Torti FM
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormono-radiotherapy of non-metastatic prostate cancers].
    Richaud P; Mazeron JJ
    Cancer Radiother; 2002 May; 6(3):175-82. PubMed ID: 12116843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant androgen suppression and external beam radiation therapy.
    Zietman AL; Smith CT
    Front Radiat Ther Oncol; 2002; 36():87-98. PubMed ID: 11842759
    [No Abstract]   [Full Text] [Related]  

  • 6. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
    Koontz BF; Lee WR
    Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    Bolla M; Gonzalez D; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Gil T; Collette L; Pierart M
    N Engl J Med; 1997 Jul; 337(5):295-300. PubMed ID: 9233866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):205. PubMed ID: 11355590
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
    Hellerstedt B
    Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
    Samant RS; Dunscombe PB; Roberts GH
    Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer--the therapeutic challenge of locally advanced disease.
    Blasko JC; Lange PH
    N Engl J Med; 1997 Jul; 337(5):340-1. PubMed ID: 9233872
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent androgen ablation as a treatment for prostate cancer.
    Wolff JM
    Front Radiat Ther Oncol; 2002; 36():66-71. PubMed ID: 11842756
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Pollack A; Horwitz EM
    Nat Clin Pract Oncol; 2005 Jan; 2(1):12-3. PubMed ID: 16264846
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation therapy for the treatment of locally advanced and metastatic prostate cancer.
    Thurman SA; Ramakrishna NR; DeWeese TL
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):423-43. PubMed ID: 11525289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.